Med-tech deal values the first seven months of the year are up more than 50% from last year. Meanwhile, M&As decreased almost 70% from the same time period in 2022.
The June dip in biopharma deal value was short-lived, with July seeing 106 deals worth $17.57 billion, up 72.03% from $10.22 billion in July 2022. In the first seven months of 2023, 778 deals were completed worth $105.39 billion, compared to 995 deals worth $105.9 billion in the same period last year, a decrease of 0.48% by value and a decrease of 21.8% by volume. The same timeframe in 2021 saw 1,240 deals valued at $107 billion, 1,228 deals worth $112.23 billion in 2020, and 963 deals totaling $93.39 billion in 2019.
Biopharmas raised $5.87 billion through 96 financings transactions in July 2023. The total amount raised is similar to the first six months of 2023 average of $5.48 billion per month, ranging from $3.74 billion in February to $8.02 billion in March of this year. Including July, the 2023 monthly average of money raised in all transactions is $5.46 billion.
Med-tech companies raised $955 million from 40 transactions in July 2023, a decrease of 12.39% from the $1.09 billion raised in July 2022. The volume of med-tech financings has increased from 32 in July 2022, though it is less than the previous six months’ average of 43 and seven-month average of 42. Compared to prior years, July 2021 saw $4.78 billion raised in 74 financings, $3.15 billion from 80 transactions in July 2020 and $1.99 billion from 41 financings in July 2019.
RSS
